The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Earnings season is when investors get a progress report about the companies in their portfolio or on their watchlist. An earnings report is generally a lagging indicator. That’s because the headline ...

The global Tissue Engineering Market , valued at US$4.3 billion in 2022, is forecasted to grow at a robust CAGR of 15.3%, ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks ...

AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

The stock's fall snapped a two-day winning streak.

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...